- Nasdaq halts trading in Genocea Biosciences (NASDAQ:GNCA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) pending news.
- Genocea's lead product candidate is GEN-003, a therapeutic vaccine for genital herpes. Positive results were achieved in a Phase 2 study.
- Arrowhead's lead product candidate is Phase 2-stage ARC-520, an RNAi therapeutic for the potential curative treatment of chronic hepatitis B infection.
Trading in Genocea Bio and Arrowhead Pharma suspended pending news
Recommended For You
About GNCAQ Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| GNCAQ | - | - |
| Genocea Biosciences, Inc. | ||